Literature DB >> 24222980

Clinical outcomes after conversion from brand-name tacrolimus (prograf) to a generic formulation in renal transplant recipients: a retrospective cohort study.

Kwaku Marfo, Samuel Aitken, Enver Akalin.   

Abstract

After kidney transplant recipients who received Prograf were switched to generic tacrolimus, most differences in the safety and effectiveness of the medications were not considered clinically relevant.

Entities:  

Year:  2013        PMID： 24222980      PMCID： PMC3814440     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  18 in total

1.  Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans.

Authors:  Michael A Fischer; Jerry Avorn
Journal:  Health Serv Res       Date:  2003-08       Impact factor: 3.402

2.  Does bioequivalence between modified cyclosporine formulations translate into equal outcomes?

Authors:  David J Taber; G Mark Baillie; Elizabeth E Ashcraft; Jeffrey Rogers; Angello Lin; Fuad Afzal; Prabhakar Baliga; P R Rajagopalan; Kenneth D Chavin
Journal:  Transplantation       Date:  2005-12-15       Impact factor: 4.939

3.  Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.

Authors:  Barbara M Davit; Patrick E Nwakama; Gary J Buehler; Dale P Conner; Sam H Haidar; Devvrat T Patel; Yongsheng Yang; Lawrence X Yu; Janet Woodcock
Journal:  Ann Pharmacother       Date:  2009-09-23       Impact factor: 3.154

4.  KDIGO clinical practice guideline for the care of kidney transplant recipients.

Authors: 
Journal:  Am J Transplant       Date:  2009-11       Impact factor: 8.086

5.  Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials.

Authors:  G A Knoll; R C Bell
Journal:  BMJ       Date:  1999-04-24

6.  Immunosuppression with generic tacrolimus and mycophenolate mofetil in renal transplant recipients: preliminary report in Chile.

Authors:  H Müller; S Solari; C Zuñiga; C Pedreros; J Troncoso; C Morente; R Ovalle; P Acosta; T Chavez; E Albornoz
Journal:  Transplant Proc       Date:  2008-04       Impact factor: 1.066

7.  Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system.

Authors:  Michele M Spence; Lynda M Nguyen; Rita L Hui; James Chan
Journal:  Pharmacotherapy       Date:  2012-10-16       Impact factor: 4.705

Review 8.  Clinical pharmacokinetics of tacrolimus.

Authors:  R Venkataramanan; A Swaminathan; T Prasad; A Jain; S Zuckerman; V Warty; J McMichael; J Lever; G Burckart; T Starzl
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

9.  Generic tacrolimus (Pan Graf) in renal transplantation: an experience of 155 recipients in India.

Authors:  S Guleria; M Kamboj; A Chatterjee; M Sharma; V Awasthy; A Dinda; S Mahajan; D Bhowmik; S Gupta; S K Agarwal; S C Tiwari
Journal:  Transplant Proc       Date:  2008-09       Impact factor: 1.066

10.  A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients.

Authors:  R R Alloway; B Sadaka; J Trofe-Clark; A Wiland; R D Bloom
Journal:  Am J Transplant       Date:  2012-07-03       Impact factor: 8.086
View more
  5 in total

1.  Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients.

Authors:  Derisha Naicker; Peter W Reed; Jane Ronaldson; Tonya Kara; William Wong; Chanel Prestidge
Journal:  Pediatr Nephrol       Date:  2017-06-28       Impact factor: 3.714

2.  The Association of Tacrolimus Formulation Switching with Trough Concentration Variability: A Retrospective Cohort Study of Tacrolimus Use Post-Kidney Transplantation Based on National Drug Code (NDC) Numbers.

Authors:  Jason J Schwartz; Edward Lee; Ashley P Butler; David P Facklam; Billy Franks; James R Spalding; Maria E Vassilakis; Gary D Thal; William D Irish
Journal:  Adv Ther       Date:  2019-04-19       Impact factor: 3.845

Review 3.  Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis.

Authors:  Amber O Molnar; Dean Fergusson; Anne K Tsampalieros; Alexandria Bennett; Nicholas Fergusson; Timothy Ramsay; Greg A Knoll
Journal:  BMJ       Date:  2015-06-22

4.  Efficacy and safety of a conversion from the original tacrolimus and mycophenolate mofetil to the generics Tacpan and Mowel after liver transplantation.

Authors:  Johanna Vollmar; Maren Christina Bellmann; Felix Darstein; Maria Hoppe-Lotichius; Jens Mittler; Michael Heise; Bernd Rüttger; Veronika Weyer; Anca Zimmermann; Hauke Lang; Peter R Galle; Tim Zimmermann
Journal:  Drug Des Devel Ther       Date:  2015-11-17       Impact factor: 4.162

5.  Immunosuppression with generic tacrolimus in liver and kidney transplantation-systematic review and meta-analysis on biopsy-proven acute rejection and bioequivalence.

Authors:  Judith Kahn; Gudrun Pregartner; Peter Schemmer
Journal:  Transpl Int       Date:  2020-02-12       Impact factor: 3.782
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.